Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorde...(Elliott Sigal chief scientific officer a...)

Date:8/27/2007

Elliott Sigal, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. "This collaboration underscores the company's commitment to investing in research and development, and reflects our strategy to identify partnerships that complement our own research efforts to enhance our innovative pipeline."

"Pfizer's agreement with Bristol-Myers Squibb reflects our efforts to build external alliances and share resources to address significant areas of unmet medical need," said Dr. Ed Harrigan, senior vice president of Pfizer Worldwide Business Development. "This Agreement is one part of a collaborative relationship with Bristol-Myers Squibb which combines the strengths of both companies in the development of two promising research programs. Pfizer continues to look for new strategic opportunities to complement our portfolio of medicines and drive long-term growth of the company."

About DGAT-1 Inhibitors

Triglycerides are the principal component of fat, which is the major repository for storage of metabolic energy in the body. DGAT-1 (diacylglycerol acyl transferase-1) is an enzyme critical to the creation of triglycerides and fat storage. Overweight and obese individuals have significantly greater triglyceride levels, making them more prone to diabetes and its associated metabolic complications. In studies of obese animals, DGAT-1 inhibitors have been shown to induce weight loss and improve glucose tolerance and lipid levels. These observations suggest DGAT-1 inhibitors may have the potential to treat obesity, diabetes and dyslipidemia.

About Pfizer

Pfizer discovers and develops innovative medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality healthcare and health system support.

About Bristol-Myers Squibb

Bristol-Myers is a glob
'/>"/>

SOURCE Bristol-Myers Squibb Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related biology technology :

1. Mirus Bio, Pfizer enter multimillion-dollar research agreement
2. Pfizer-Pharmacia Fallout Gives Celltech A CEO
3. Sale of Norlight Telecommunications is finalized
4. WARF enters licensing agreements for stem cell products
5. Quick peeks, Clawback Agreements, and the rules of electronic discovery
6. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
7. WARF expands license agreement with Advanced Cell Technology
8. Lucigen Corp. enters global licensing agreement
9. GE Healthcare enters agreement with Canadian health authority
10. New angel capital centered on GenTel agreement with big pharma
11. Prodesse enters patent agreement with Roche